Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 18, 2016. The report serves as a transaction notification regarding a specific securities transaction involving a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It is limited to a specific transaction detail:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Type: Acquisition of Ordinary Shares following the re-investment of dividends paid on July 14, 2016.
- Volume: 6,989 shares.
- Price: £16.5875 per share.
- Location: London Stock Exchange (XLON).
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It solely documents a routine dividend reinvestment transaction by the CEO.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. The document is a regulatory disclosure of a PDMR transaction.
Investor Verification Points
- Verify the identity of the PDMR involved: Sir Andrew Witty (CEO).
- Confirm the transaction date (July 14, 2016) and execution venue (London Stock Exchange).
- Note that this transaction represents a dividend reinvestment, not an open market purchase or sale.
- Recognize that this filing does not contain quarterly or annual financial performance data.